To evaluate the efficacy, safety, and toleration of eplerenone in the treatment of children aged 6 to 16 years with high blood pressure. The study will last approximately 10 weeks and about 320 patients will participate.

Inclusion Criteria:

• 6-16 years old male and female
• Systolic blood pressure greater than or equal to the 95th percentile for age, gender, and height, measured on at least 3 separate occasions

Exclusion Criteria:

• K/DOQI classification of stages of chronic kidney disease equal to or greater than 3
• Serum or whole blood potassium > 5.5 mEq/L